ReviewCurrent opinion in pharmacology2015
How does ketamine elicit a rapid antidepressant response?
Review in Current opinion in pharmacology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05357040 (Evaluation of the Antidepressant Effects of Nitrous Oxide in People With Major Depressive Disorder), which is not on this map. Cited by 61 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Evaluation of the Antidepressant Effects of Nitrous Oxide in People With Major Depressive Disorder
Who cites it
61 citing papers in PubMed, 2 syntheses or guidelines pooled it, 105 citations in OpenAlex.
- Efficacy and safety of ketamine and esketamine in reducing the incidence of postpartum depression: an updated systematic review and meta-analysis.BMC pregnancy and childbirth · 2025Pooled it
- Alterations in brain synaptic proteins and mRNAs in mood disorders: a systematic review and meta-analysis of postmortem brain studies.Molecular psychiatry · 2022Pooled it
- Group-Based Symptom Trajectory of Intramuscular Administration of Scopolamine Augmentation in Moderate to Severe Major Depressive Disorder: A Post-Hoc Analysis.Neuropsychiatric disease and treatment · 2023Trial
- The effect of ketamine on preventing postpartum depression.Journal of medicine and lifeTrial
- State-specific inhibition of NMDA receptors by memantine provides insight into NMDAR channel blocker tolerability.Science advances · 2026Article
- Synaptic basis of rapid antidepressant action.European archives of psychiatry and clinical neuroscience · 2025Review
- Gut-Brain Axis in Mood Disorders: A Narrative Review of Neurobiological Insights and Probiotic Interventions.Biomedicines · 2025Review
- Allosteric inhibition of NMDA receptors by low dose ketamine.Molecular psychiatry · 2025Article
- Psilocybin desynchronizes the human brain.Nature · 2024Article
- ThePhilosophical transactions of the Royal Society of London. Series B, Biological sciences · 2024Review
- Ketamine in Substance Use Disorder Treatment: A Narrative Review.Alpha psychiatry · 2024Review
- The Psychedelic Future of Post-Traumatic Stress Disorder Treatment.Current neuropharmacology · 2024Review
- Cerebrospinal fluid exploratory proteomics and ketamine metabolite pharmacokinetics in human volunteers after ketamine infusion.iScience · 2023Article
- Psilocybin desynchronizes brain networks.medRxiv : the preprint server for health sciences · 2023Article
- Functional ultrasound detects frequency-specific acute and delayed S-ketamine effects in the healthy mouse brain.Frontiers in neuroscience · 2023Article
- Prophylactic (R,S)-Ketamine Is Effective Against Stress-Induced Behaviors in Adolescent but Not Aged Mice.The international journal of neuropsychopharmacology · 2022Article
- Anesthetic care for electroconvulsive therapy.Anesthesia and pain medicine · 2022Review
- Acute (Frontiers in neuroscience · 2022Article
- The Regulation of Glutamate Transporter 1 in the Rapid Antidepressant-Like Effect of Ketamine in Mice.Frontiers in behavioral neuroscience · 2022Article
- Ketamine Alters Functional Plasticity of Astroglia: An Implication for Antidepressant Effect.Life (Basel, Switzerland) · 2021Review
1 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
A single sub-psychotomimetic dose of ketamine, an ionotropic glutamatergic n-methyl-D-aspartate (NMDA) receptor antagonist, produces a fast-acting antidepressant response in patients suffering from major depressive disorder. Depressed patients report alleviation of core symptoms within 2 h of a single low-dose intravenous infusion of ketamine with effects lasting up to 2 weeks. The rapidity of ketamine action implies that major symptoms of depression can be alleviated without substantial structural plasticity or circuit rewiring. Therefore, the ability of ketamine to exert a rapid effect provides a unique opportunity to elucidate the types of acute synaptic plasticity changes that can be recruited to counter depression symptoms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.